Isofol Medical AB (DE:5IU)
FRANKFURT:5IU
5IU Stock Chart & Stats
€0.05
€0.01(5.26%)
At close: 4:00 PM EST
€0.05
€0.01(5.26%)
Day’s Range― - ―
52-Week Range€0.04 - €0.16
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€16.83M
Enterprise Value€141.15M
Total Cash (Recent Filing)€126.99M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.44
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding281,107,240
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)1.46
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / No DebtA debt-free balance sheet materially reduces financing risk and interest burdens for a pre-commercial biotech. This gives management optionality to prioritize clinical development and partnering discussions without immediate debt-servicing constraints, preserving flexibility during pivotal trials.
Improved Cash Burn ControlOperating cash outflows have been materially reduced from early-decade extremes, reflecting tighter cost control or program reprioritization. Lower burn extends runway per unit of funding, increases the probability of reaching clinical inflection points before another large financing, and makes partnerships more feasible.
Focused Asset And Partnering ModelIsofol's model concentrates resources on a single lead candidate and seeks regulatory advancement and external commercialization partners. This asset-focused, partnership-oriented strategy is capital-efficient long term and aligns incentives with larger pharma, reducing the need to build costly commercial infrastructure internally.
Bears Say
No Recent RevenueThe collapse to zero reported revenue demonstrates the company remains fully pre-commercial, eliminating internal cash generation to fund R&D or operations. Persistent absence of product sales increases reliance on external capital or partnering and raises dilution and execution risk over the medium term.
Large And Persistent LossesSignificant annual losses and continued negative operating cash flow indicate the business is consuming substantial resources to advance programs. Ongoing deficits reduce financial flexibility, heighten fundraising needs, and can force accelerated asset sales or unfavorable deals if clinical timelines slip.
Eroding Equity CushionA marked decline in shareholders' equity over several years shows accumulated losses and/or capital structure changes have materially weakened the balance sheet. Reduced equity limits shock absorption, increases dependence on capital markets, and can weaken negotiating leverage with potential partners or acquirers.
Isofol Medical AB News
5IU FAQ
What was Isofol Medical AB’s price range in the past 12 months?
Isofol Medical AB lowest stock price was €0.04 and its highest was €0.16 in the past 12 months.
What is Isofol Medical AB’s market cap?
Isofol Medical AB’s market cap is €16.83M.
When is Isofol Medical AB’s upcoming earnings report date?
Isofol Medical AB’s upcoming earnings report date is May 19, 2026 which is in 53 days.
How were Isofol Medical AB’s earnings last quarter?
Isofol Medical AB released its earnings results on Feb 18, 2026. The company reported -€0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.005.
Is Isofol Medical AB overvalued?
According to Wall Street analysts Isofol Medical AB’s price is currently Overvalued.
Does Isofol Medical AB pay dividends?
Isofol Medical AB does not currently pay dividends.
What is Isofol Medical AB’s EPS estimate?
Isofol Medical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Isofol Medical AB have?
Isofol Medical AB has 281,107,240 shares outstanding.
What happened to Isofol Medical AB’s price movement after its last earnings report?
Isofol Medical AB reported an EPS of -€0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.326%.
Which hedge fund is a major shareholder of Isofol Medical AB?
Currently, no hedge funds are holding shares in DE:5IU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Isofol Medical AB
Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.
Technical Analysis
Xintela AB
―
IRLAB Therapeutics AB Class A
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―
Bio-Works Technologies AB
―